We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+1.61%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$71.7B
AUM Growth
+$2.34B
Cap. Flow
+$1.49B
Cap. Flow %
2.08%
Top 10 Hldgs %
21.97%
Holding
3,809
New
183
Increased
1,708
Reduced
1,572
Closed
206

Sector Composition

Rank Sector Weight
1 Technology 10.59%
2 Financials 9.51%
3 Healthcare 8.04%
4 Industrials 6.62%
5 Communication Services 5.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ZTS icon
126
Zoetis
ZTS
$30B
$106M 0.15%
847,475
+28,679
+4% +$3.46M
BMY icon
127
Bristol-Myers Squibb
BMY
$132B
$105M 0.15%
2,073,062
+296,256
+17% +$13.9M
SBUX icon
128
Starbucks
SBUX
$120B
$105M 0.15%
1,184,134
-89,219
-7% -$8.27M
RTN
129
DELISTED
Raytheon Company
RTN
$105M 0.15%
533,531
+21,538
+4% +$3.99M
VTR icon
130
Ventas
VTR
$47.9B
$104M 0.15%
1,429,966
-10,430
-0.7% -$740K
JPST icon
131
JPMorgan Ultra-Short Income ETF
JPST
$40.3B
$103M 0.14%
2,049,366
+617,345
+43% +$31.2M
LIN icon
132
Linde
LIN
$226B
$103M 0.14%
532,090
-40,808
-7% -$7.91M
NVS icon
133
Novartis
NVS
$297B
$103M 0.14%
1,183,198
-454,627
-28% -$40.8M
VCSH icon
134
Vanguard Short-Term Corporate Bond ETF
VCSH
$44.7B
$102M 0.14%
1,259,759
+289,254
+30% +$23.4M
NKE icon
135
Nike
NKE
$61.9B
$100M 0.14%
1,065,705
+34,816
+3% +$2.99M
EL icon
136
Estee Lauder
EL
$32B
$98.9M 0.14%
496,986
+43,641
+10% +$8.34M
SYY icon
137
Sysco
SYY
$40.3B
$98.1M 0.14%
1,235,825
-49,501
-4% -$3.63M
VTI icon
138
Vanguard Morningstar Total Stock Market ETF
VTI
$684B
$98.1M 0.14%
649,398
+61,297
+10% +$9.24M
AGN
139
DELISTED
Allergan plc
AGN
$97.5M 0.14%
579,611
-107,068
-16% -$17.4M
LYB icon
140
LyondellBasell Industries
LYB
$19.2B
$96.1M 0.13%
1,073,955
+392,474
+58% +$32M
NGG icon
141
National Grid
NGG
$81.3B
$93.1M 0.13%
1,945,799
-53,788
-3% -$2.49M
ACN icon
142
Accenture
ACN
$108B
$92.8M 0.13%
482,301
+16,162
+3% +$3.13M
KSU
143
DELISTED
Kansas City Southern
KSU
$92.8M 0.13%
697,304
+44,219
+7% +$5.51M
TMO icon
144
Thermo Fisher Scientific
TMO
$220B
$92.7M 0.13%
318,156
-243
-0.1% -$69.6K
CNK icon
145
Cinemark Holdings
CNK
$4.32B
$91.9M 0.13%
2,378,472
+21,692
+0.9% +$829K
BX icon
146
Blackstone
BX
$110B
$91.2M 0.13%
1,867,642
+585,848
+46% +$28.6M
NFLX icon
147
Netflix
NFLX
$309B
$91.2M 0.13%
3,407,630
-236,020
-6% -$7.38M
GLD icon
148
SPDR Gold Trust
GLD
$141B
$90.4M 0.13%
650,750
+146,402
+29% +$20.4M
PPL
149
PPL Corp
PPL
$26.7B
$90.2M 0.13%
2,865,485
+16,387
+0.6% +$495K
CM icon
150
Canadian Imperial Bank of Commerce
CM
$108B
$90M 0.13%
2,179,316
+787,244
+57% +$30.9M

Similar funds

Raymond James & Associates's Q3 2019 Portfolio in Review

As of Q3 2019, Raymond James & Associates held 3,809 positions worth $71.7B, up 3.4% from $69.4B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Raymond James & Associates's Q3 2019 filing shows 183 new, 1,708 increased, 1,572 reduced and 206 closed positions. Its largest new stake was Change Healthcare Inc. Common Stock: 949,970 shares worth $11.5M. The largest sale was Microchip Technology, an estimated $155M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q3 2019 buy was Change Healthcare Inc. Common Stock: 949,970 shares worth $11.5M.
  • Raymond James & Associates added most to Comcast in Q3 2019, an estimated $203M increase.
  • Raymond James & Associates's biggest Q3 2019 reduction was Microchip Technology, cutting an estimated $155M.
  • Raymond James & Associates fully exited Anadarko Petroleum in Q3 2019, selling an estimated $89.3M.
  • Raymond James & Associates's ten largest holdings make up 22% of its $71.7B portfolio in Q3 2019.
  • Raymond James & Associates opened 183 new positions and closed 206 in Q3 2019.
  • Raymond James & Associates's portfolio value rose 3.4% quarter-over-quarter to $71.7B.

Based on Raymond James & Associates's 13F filing for Q3 2019, filed 7 Nov 2019.